Bengaluru-based diagnostics startup Orange Health Labs has reported ₹138 crore in revenue for FY26, with an annual revenue run rate (ARR) of ₹180 crore.
The company, which operates across Bengaluru, Mumbai, Delhi-NCR and Hyderabad, has also achieved operational profitability across cities, with its largest market—Bengaluru—leading on margins.
“We have grown from ₹85 crore last year to ₹138 crore this year, a 65 per cent annual growth rate. At an annualised level, we have exited at ₹180 crore and expect to grow another 60–70 per cent next year,” said Tarun Bhambra, co-founder of Orange Health Labs.
Bengaluru, which contributes nearly half of the company’s revenue, is already profitable. “The city is operating at about ₹85–90 crore run rate and is delivering 20 per cent EBITDA profitability after all costs,” Bhambra said, adding that more cities are expected to break even over the next year.
The company’s growth aligns with a broader shift toward at-home diagnostics, accelerated after the pandemic. “Five years ago, at-home testing was under 10 per cent of the industry; today it is closer to 20–25 per cent and growing faster than the overall market,” he said.
Preventive healthcare is also gaining traction. “Earlier, preventive testing was about 8–12 per cent of the market; today it is 25–30 per cent. For us, around 35–40 per cent of our business is preventive,” Bhambra noted.
A key differentiator for Orange Health has been its logistics-led model, enabling faster service. The company has reduced sample collection time from 60 minutes to 30 minutes and is working toward near-instant bookings.
“We have built a hub-based, FedEx-like reverse logistics network where samples are dropped at automated hubs instead of being carried back to a central lab each time. This allows faster turnaround and better utilisation,” he said.
To tap the largely offline diagnostics market, still about 75 per cent of the industry—the company is also scaling its physical footprint. It has expanded from 15 to over 75 company-owned collection centres in the past year and plans to reach 200 centres by the end of the fiscal.
Looking ahead, Orange Health plans to expand to 10–12 cities over the next two to three years and enter adjacent segments such as radiology and scans.
“We don’t see ourselves as just a pathology company. We want to be a broader health measurement platform,” Bhambra said.